Proteostasis Therapeutics (PTI) Stock Price, News & Analysis

Company Overview

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.00 to $22.42
• 52-Week Range: N/A
• Volume: 9,405 shs
• Average Volume: 1.04 million shs
• Market Capitalization: $37.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTI Stock Analysis - Frequently Asked Questions

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) posted its quarterly earnings results on Monday, November, 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01.

When did Proteostasis Therapeutics IPO?

Proteostasis Therapeutics (PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Rite Aid (RAD) and

Company Calendar

• Last Earnings: 11/16/2020
• Today: 4/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PTI
• CIK: 1445283
• Web: www.proteostasis.com
• Phone: 617-225-0096
• Fax: N/A
• Employees: 44
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-59,130,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -75.39%
• Return on Assets: -55.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.69
• Quick Ratio: 6.69

Sales & Book Value

• Annual Sales: $5 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.22 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 52,185,000
• Free Float: N/A
• Market Cap: $37.57 million
• Optionable: Not Optionable
• Beta: 1.16